Mechanisms and implications of imatinib resistance mutations in BCR-ABL

V Nardi, M Azam, GQ Daley - Current opinion in hematology, 2004 - journals.lww.com
Current opinion in hematology, 2004journals.lww.com
The most common mechanism of relapse for CML patients treated with Imatinib is the
appearance of point mutations in the BCR-ABL oncogene that confer resistance to this drug.
Insights into the emerging problem of resistance should promote the rational development of
alternative, synergistic, and potentially curative treatment strategies.
Summary
The most common mechanism of relapse for CML patients treated with Imatinib is the appearance of point mutations in the BCR-ABL oncogene that confer resistance to this drug. Insights into the emerging problem of resistance should promote the rational development of alternative, synergistic, and potentially curative treatment strategies.
Lippincott Williams & Wilkins